TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07297979: A Phase 1b Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Xaluritamig in Adult, Adolescent and Pediatric Participants With Relapsed or Refractory Ewing Sarcoma

Sponsor: Amgen · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 50 pts

Competing Trials Overlap

7 Active Trials

Excess Burn Exposure

$2,073,456

Rescue Site Savings

+$1,382,304

Unlock Full NCT07297979 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07297979 Rescue Dossier →